Open Access

An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer

  • Authors:
    • Haiqun Xia
    • Weixuan Yu
    • Ming Liu
    • Hong Li
    • Wei Pang
    • Libin Wang
    • Yunda Zhang
  • View Affiliations

  • Published online on: July 26, 2019     https://doi.org/10.3892/ol.2019.10669
  • Pages: 2985-2994
  • Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer (BC) is one of the most aggressive malignancies worldwide among females. Matrix metalloproteinases (MMPs), as the most abundant class of non‑serine proteases present in invasive and metastatic tumors, can regulate a variety of alterations in the microenvironment during tumor progression. However, the differential expression of MMPs and its prognostic values in BC is yet to be elucidated. In this research, using the ONCOMINE dataset, The Cancer Genome Atlas, Breast Cancer Gene‑Expression Miner v4.1 (Bc‑GenExMiner), Kaplan‑Meier Plotter and cBioPortal, the transcriptional MMPs and survival outcome data of patients with BC was compared. It was indicated that mRNA levels of MMP1/3/9/10/11/12/13 were increased compared with non‑tumor tissues, whereas mRNA expression of MMP2/16/19/23B/28 was lower in BC tissues. Kaplan‑Meier plots showed that high mRNA levels of MMP2/10/16/19/20/23B/27 in patients with BC were associated with better recurrence‑free survival. In contrast, high MMP1/8/9/11/12 conferred worse RFS rate. Meanwhile, high transcription levels of MMP1/3/11/12/13 predicted shorter distant metastasis‑free survival, while high levels of MMP1/12 demonstrated worse overall survival in patients with BC. From Bc‑GenExMiner, it was indicated that high expression of MMP16/20 was correlated with better prognosis, while MMP1/9/11/12/13/14/15 exerted a negative effect on patient prognosis. The integrative bioinformatics analysis performed in the present study suggests that MMP1/9/12/16, compared with other MMPs, are potentially appropriate targets for targeted therapy in patients with BC.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xia, H., Yu, W., Liu, M., Li, H., Pang, W., Wang, L., & Zhang, Y. (2019). An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer. Oncology Letters, 18, 2985-2994. https://doi.org/10.3892/ol.2019.10669
MLA
Xia, H., Yu, W., Liu, M., Li, H., Pang, W., Wang, L., Zhang, Y."An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer". Oncology Letters 18.3 (2019): 2985-2994.
Chicago
Xia, H., Yu, W., Liu, M., Li, H., Pang, W., Wang, L., Zhang, Y."An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer". Oncology Letters 18, no. 3 (2019): 2985-2994. https://doi.org/10.3892/ol.2019.10669